MAM
American Swan is PWI’s official lifestyle clothing partner
MUMBAI: Indian online fashion and lifestyle brand American Swan announced its association with the IPL team -Pune Warriors India (PWI). The brand is the official lifestyle clothing partner for the team this season and the Warriors will be seen wearing co-branded American Swan apparel. This association will be promoted by both partners through their digital properties; their official site and social media channels.
As a part of its social & digital marketing campaign, American Swan will leverage the Pune Warriors association to create a social buzz. American Swan’s customers, Facebook fans and twitter followers will get an opportunity to participate in contests, promos and campaigns on their social media channels and e-commerce website; these will include a chance to meet the IPL franchise’s star players, win passes to their matches and also win signed merchandise.
American Swan director, CEO Anurag Rajpal said, “We are very happy to announce our partnership as the official lifestyle clothing partner of PWI. The brand: its products, brand communication as well as our marketing approach are aimed to connect with the youth and young achievers.”
PWI spokesperson Abhijit Sarkar said, “We had a fair expectation of American Swan brand and products considering their approach to fashion and lifestyle. However, the products, which have been customised for our team by the brand, have truly exceeded our expectations. The brand’s style philosophy goes very well with our team’s spirit.”
American Swan adds that the sales that the brand has witnessed from its own portal as well as through aggregators like Jabong, Myntra, Yebhi, Flipkart, Snapdeal and Homeshop18 is encouraging. Online retail it notes has seen a heavy overlap with social networking and search due to aggressive marketing and strong inclination towards social commerce. This insight has been the driving force behind American Swan opting for Digital Marketing as the primary channel to build the brand as well as drive trials and purchase.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
